The SLC27A2 antibody is a research tool designed to detect and study the solute carrier family 27 member 2 (SLC27A2), a protein encoded by the *SLC27A2* gene in humans. Also known as fatty acid transport protein 2 (FATP2), SLC27A2 plays a critical role in cellular fatty acid uptake and metabolism, particularly in lipid biosynthesis and energy homeostasis. It is a transmembrane protein predominantly expressed in tissues with high lipid metabolic activity, such as the liver, kidney, and adipose tissue. Structurally, SLC27A2 contains an N-terminal AMP-binding domain and multiple transmembrane regions, facilitating its function in activating and transporting long-chain fatty acids into cells.
Antibodies targeting SLC27A2 are widely used in biomedical research to investigate its expression patterns, subcellular localization, and involvement in metabolic disorders, including obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). They are also employed to explore SLC27A2's potential role in cancer progression, as aberrant lipid metabolism is a hallmark of tumorigenesis. These antibodies are typically validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Recent studies highlight SLC27A2 as a therapeutic target, driving demand for high-specificity antibodies to support drug development and mechanistic studies. Researchers prioritize antibodies with minimal cross-reactivity to other SLC27 family members to ensure accurate experimental outcomes.